Ignite Creation Date:
2025-12-24 @ 1:06 PM
Ignite Modification Date:
2026-02-24 @ 12:14 AM
Study NCT ID:
NCT00564161
Status:
WITHDRAWN
Last Update Posted:
2016-09-02
First Post:
2007-11-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants
Sponsor:
Hadassah Medical Organization
Organization:
Study Overview
Official Title:
VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants
Status:
WITHDRAWN
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We hypothesize that misexpression of vascular endothelial growth factor (VEGF) in the Cerebrospinal fluid of preterm infants can be used as a biomarker to predict the risk for developing white matter damage.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 606060-HMO-CTIL | None | None | View |